Paraneoplastic Cerebellar Degeneration
The Importance of Including CDR2L as a Diagnostic Marker
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 21, 2020
- Accepted in final form December 9, 2020
- First Published February 2, 2021.
Author Disclosures
- Ida Herdlevær, MSc,
- Mette Haugen, BSc,
- Kibret Mazengia, MSc,
- Cecilie Totland, PhD and
- Christian Vedeler, MD, PhD
- Ida Herdlevær, MSc,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Helse Vest, Norway; #F-11533-D11661; PhD stipend; 2018-2021
NONE
Torbjorg Hauges Legacy, Univeristy of Bergen, Norway
NONE
NONE
NONE
NONE
NONE
NONE
- Mette Haugen, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kibret Mazengia, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cecilie Totland, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Vedeler, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed—Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.
- Correspondence
Ida Herdlevær idaherd{at}gmail.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromesBenoît Déchelotte, Sergio Muñiz-Castrillo, Bastien Joubert et al.Neurology: Neuroimmunology & Neuroinflammation, March 13, 2020 -
Article
Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degenerationChristian Probst, Lars Komorowski, Esther de Graaff et al.Neurology - Neuroimmunology Neuroinflammation, February 26, 2015 -
Article
Autoantibodies Against the Purkinje Cell Protein RGS8 in Paraneoplastic Cerebellar SyndromeRamona Miske, Madeleine Scharf, Patrick Stark et al.Neurology: Neuroimmunology & Neuroinflammation, March 29, 2021 -
Article
Clinical significance of Kelch-like protein 11 antibodiesEstibaliz Maudes, Jon Landa, Amaia Muñoz-Lopetegi et al.Neurology: Neuroimmunology & Neuroinflammation, January 17, 2020